Key facts
- This page summarizes William Valle's Form 4 filing for TriSalus Life Sciences, Inc. (TLSI).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 31 Jan 2025, 18:00.
William Valle - 29 Jan 2025 Form 4 Insider Report for TriSalus Life Sciences, Inc. (TLSI)
- Reporting relationship
- Director
- Issuer ticker
- TLSI
- Reported as of
- 29 Jan 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 31 Jan 2025, 18:00:07 UTC
- Prior SEC filing
- 18 Jul 2024
- Next SEC filing
- 27 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ James E. Young, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
William Valle filed Form 4 for TriSalus Life Sciences, Inc. (TLSI) on 31 Jan 2025.
Change
- Previous filing in this sequence was filed on 18 Jul 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TLSI
transaction
Derivative
Director Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +35,000
- Change %
- Price
- $0.000000
- Shares after
- 35,000
- Date
- 29 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 35,000
- Exercise price
- $4.89
- Footnotes
- F1
TLSI
transaction
Derivative
Director Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +6,250
- Change %
- Price
- $0.000000
- Shares after
- 6,250
- Date
- 29 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 6,250
- Exercise price
- $4.89
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The shares subject to this stock option vest in three equal annual installments from the vesting commencement date of January 29, 2025, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.
Footnote F2
The shares subject to the option shall fully vest on the one-year anniversary of the grant date of January 29, 2025, provided that the shares subject to the option will in any case be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's continued service with the Issuer.